Global Growth Hormone Disorder Treatment Market, By Type (Acquired GHD, Congenital GHD, Idiopathic GHD, Others), Disorders (Small for Gestational Age (SGA), Short Stature, Idiopathic Short Stature, Turner Syndrome, Noonan Syndrome, Prader-Willi Syndrome, Laron Syndrome, Gigantism & Acromegaly, Others), Treatment (Diagnosis, Treatment, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Growth Hormone Disorder Treatment Market Analysis and Size
According to the American Academy of Pediatrics, growth hormone deficiency among humans is a rare condition and affects around less than one in 3,000 to one in 10,000 children in U.S. Human growth hormone medications are extensively available in today’s market-creating awareness about its health benefits which is further the revenue generation of several manufacturing companies. The demand for such medication is increasing the rate of growth hormone diseases.
Data Bridge Market Research analyses a growth rate in the global growth hormone disorder treatment market in the forecast period 2023-2030. The expected CAGR of global growth hormone disorder treatment market is tend to be around 9.11% in the mentioned forecast period. The market was valued at USD 5,538.85 million in 2022, and it would grow upto USD 11,125.92 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Growth Hormone Disorder Treatment Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Type (Acquired GHD, Congenital GHD, Idiopathic GHD, Others), Disorders (Small for Gestational Age (SGA), Short Stature, Idiopathic Short Stature, Turner Syndrome, Noonan Syndrome, Prader-Willi Syndrome, Laron Syndrome, Gigantism & Acromegaly, Others), Treatment (Diagnosis, Treatment, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Teva Pharmaceutical Industries Ltd (Israel), Amneal Pharmaceutical Inc (U.S.), Mayne Pharma Group Limited (Australia), Merck KGaA (Germany), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), PT. Daewoong Pharmaceutical Company (South Korea), Genentech, Inc (U.S.), Bausch Health Companies Inc. (Canada), Lilly (U.S.), Ipsen Pharma (France), Ferring B.V. (Switzerland)
Growth hormone disorder is a rare type of condition that is typically characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. This kind of hormones can be present since birth and cause serious genetic mutation or structural defects in the brain. The growth hormone disorders can be acquired in the later years due to the presence of severe infection, trauma among others. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy.
Global Growth Hormone Disorder Treatment Market Dynamics
- Increasing Trend of urban lifestyle
Urban lifestyles and deteriorating food habits are projected to increase the demand for human growth hormone drugs and diverse treatment facilities. There has been an increase in stress and sleeplessness because of the hectic life patterns of the citizens working in cities. This is causing huge hormonal imbalance in the body. Medication growth hormones help in such situations and thus are becoming more popular among youngsters and old people around the world.
- Increase in Growth Disorders
There has been a continuing increase in public understanding regarding the use of synthetic growth hormone therapy. The expanding industrial research for the causes of growth disorders, along with an improving incidence of diagnosis, led to an increase in market growth. Many growth-related issues such as adult growth hormone deficiency, pediatric growth hormone deficit, idiopathic low stature, and hereditary illnesses such as Turner syndrome and Prader-Willi syndrome are contributing enough to boost the market size. Globally, 1 in 3800 children suffers from a growth hormone deficit. Turner syndrome affects about 1 in every 2000 females, and Prader-Willi syndrome affects 1 in every 30,000 persons. Thus, it boosts the market growth.
- Increased Clinical Studies and Related Activities
Robust product pipeline and wide R&D activities for the development of novel growth hormone therapies are projected to be the major factors pushing the market growth. For instance, in September 2018, Novo Nordisk presented Phase II clinical trial data of its investigational GH therapy, Somapacitan, that is specified for the treatment of pediatric growth hormone deficiency. In addition to this, in May 2019, Ascendis Pharma A/S published results from the Phase III clinical trial of its TransCon hGH, that is indicated for pediatric growth hormone deficiency.
- Growing Government Initiatives
The various initiatives taken by numerous government and private organizations to spread awareness about growth hormone deficiencies and human growth hormone treatment are projected to drive the market. Each year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), which is a U.S.-based nonprofit charitable organization, celebrates International Children’s Growth Awareness Day to spread awareness about the diagnosis and treatment of growth hormone disorders to initiate fast recovery among humans, particularly children.
- Risk of Complications
The growth hormone disorder treatment market has a high risk of complications. Complications such as the possible side effects of growth hormone therapy which include knee, hip, or other joint pain; allergic reactions, such as rash, swelling, or hives, and an increase in blood sugar levels are witnessed post the therapy. Thus, it hampers the market growth.
- High Cost
The huge expenditure associated with these drugs hamper the market growth. The growth hormone disorder drugs cost high and thus sometimes becomes unaffordable for the lower economic groups.
This global growth hormone disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global growth hormone disorder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Growth Hormone Disorder Treatment Market
COVID-19 left a major impact on almost every business sector and in turn is hampering the pharmaceutical sector as well. Human growth hormone injections dipped considerably during the pandemic year starting in March 2020. COVID-19 left a negative impact on the global growth hormone disorder treatment market. In the post-pandemic era, there was an increasing demand for human growth hormone treatment and drugs because of patients' vulnerability to getting infected by the virus. Furthermore, a report published by the magazine frontier stated that patients suffering from Prader-Willi syndrome may get late onset symptoms after getting infected positively increased the demand for human growth hormone therapy in the U.S. and beyond.
- In February 2021, Pfizer and OPKO health Inc. announced that the European Medicines Agency had approved Somatrogon for treating juvenile growth hormone deficient patients.
- In August 2021, Ascendis Pharma received FDA approval for their SKYTROFA injectable in August 2021. The company is set to receive a huge turnover after the product is released in the global market.
Global Growth Hormone Disorder Treatment Market Scope
The global growth hormone disorder treatment market is segmented on the basis of type, disorders, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Acquired GHD
- Congenital GHD
- Idiopathic GHD
- Small for Gestational Age (SGA)
- Short Stature
- Idiopathic Short Stature
- Turner Syndrome
- Noonan Syndrome
- Prader-Willi Syndrome
- Laron Syndrome
- Gigantism & Acromegaly
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Growth Hormone Disorder Treatment Market Regional Analysis/Insights
The global growth hormone disorder treatment market is analyzed and market size insights and trends are provided by type, disorders, distribution channel and end user as referenced above.
The major countries covered in the global growth hormone disorder treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global growth hormone disorder treatment market throughout the forecast period due to the region's increased R&D activities on growth hormones and well-established health care infrastructure.
Asia-Pacific dominates the market due to increased technological advancement and the increasing prevalence of chronic and metabolic diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Growth Hormone Disorder Treatment Market Share Analysis
The global growth hormone disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global growth hormone disorder treatment market
Key players operating in the global growth hormone disorder treatment market market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Amneal Pharmaceutical Inc (U.S.)
- Mayne Pharma Group Limited (Australia)
- Merck KGaA (Germany)
- Sanofi (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- PT. Daewoong Pharmaceutical Company (South Korea)
- Genentech, Inc (U.S.)
- Bausch Health Companies Inc. (Canada)
- Lilly (U.S.)
- Ipsen Pharma (France)
- Ferring B.V. (Switzerland)